← All trials
NCT04808245
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 6, 2021
- Primary completion
- Mar 31, 2024
- Completion date
- Mar 31, 2024
- First posted
- Mar 22, 2021
- Last posted
- Jul 30, 2021
- Enrollment
- 15
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- German Cancer Research CenterLead sponsor
- RocheCollaborator
- Johannes Gutenburg UniversityCollaborator
- Humboldt UniversityCollaborator
- Deutsche Krebshilfe e.V.Collaborator
- German Cancer Research CenterOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.